BioGaia AB (publ)

Stockholm Stock Exchange BIOG-B.ST

BioGaia AB (publ) Shareholders' Equity for the year ending December 31, 2023: USD 200.39 M

BioGaia AB (publ) Shareholders' Equity is USD 200.39 M for the year ending December 31, 2023, a 6.39% change year over year. Shareholders' equity are the residual interest in the assets of a company after deducting liabilities, representing the shareholders' ownership claim.

BioGaia AB (publ) Shareholders' Equity for the year ending December 31, 2022 was USD 188.37 M, a -8.87% change year over year.
BioGaia AB (publ) Shareholders' Equity for the year ending December 31, 2021 was USD 206.70 M, a -2.34% change year over year.
BioGaia AB (publ) Shareholders' Equity for the year ending December 31, 2020 was USD 211.64 M, a 291.66% change year over year.
BioGaia AB (publ) Shareholders' Equity for the year ending December 31, 2019 was USD 54.04 M, a -4.88% change year over year.

Key data

Date	Shareholders' Equity	Minority Interest	Total Equity	Total Stockholders Equity and Liabilities

Stockholm Stock Exchange: BIOG-B.ST

BioGaia AB (publ)

CEO	Ms. Theresa P. Agnew
IPO Date	Jan. 3, 2000
Location	Sweden
Headquarters	Kungsbroplan 3
Employees	222
Sector	Consumers Staples
Industries Dairy & Milk Baby & Childcare Biotechnology Frozen Foods Non-Alcoholic Beverages Personal Care Pharmaceuticals Plastics

Description

BioGaia AB (publ) develops, markets, and sells probiotic products with documented health benefits worldwide. It operates through three segments: Pediatrics, Adult Health, and Other. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures that are used as an ingredient in infant formula. The Adult Health segment provides gut health tablets and oral health lozenges products, as well as cultures, which are used as an ingredient in a licensee's dairy product. The Other segment provides packaging solutions. The company offers its products in the areas of infantile colic and digestive health in children; antibiotic-associated and acute diarrhoea; gingivitis; periodontal disease; general health; Helicobacter pylorithe gastric ulcer bacterium; and low bone density. It offers its products under the BioGaia brand name. BioGaia AB (publ) was founded in 1990 and is headquartered in Stockholm, Sweden.

Key trends

Past 5 years